Risk of keratinocyte carcinomas with vitamin D and calcium supplementation: a secondary analysis of a randomized clinical trial.

What Was Tested

This randomized controlled trial looks at Vitamin D, K2, Magnesium and Zinc.

Who Took Part

The study group was 2259 men.

PubMed indexes the participants as middle-aged adults and older adults, both men and women.

How the Study Was Run

The design is described as randomized, double-blind, placebo-controlled and multicenter.

Because people in this Vitamin D, K2, Magnesium and Zinc study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Neither the men nor the staff measuring them knew who was on Vitamin D, K2, Magnesium and Zinc, so expectations could not easily colour the readings.

A placebo (an inactive look-alike) gave the Vitamin D, K2, Magnesium and Zinc group a baseline to be compared against.

Running at several centres spread the Vitamin D, K2, Magnesium and Zinc study over different clinics and patient groups.

Reports of incident BCC or SCC were confirmed from pathology records.

What Was Measured

PubMed files the paper under topics including Calcium, Carcinoma, Basal Cell Carcinoma, Carcinoma, Squamous Cell, Dietary Supplements, Risk Factors and Vitamin D.

Author keywords: cutaneous squamous cell carcinoma, keratinocyte carcinomas and nonmelanoma skin cancer.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc in 2259 men.

With several hundred people or more, it is a fairly large study for this kind of research.

Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2020 (The American journal of clinical nutrition), a journal based in United States.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.